285. Unlocking the Hidden Pearls of Using Tricuspid Annulus Plane Systolic Excursion on Pulmonary Arterial Systolic Pressure Ratio in the Prognostic Assessment of Suspected But Unconfirmed or Mild Pulmonary Hypertension.295. High-Flow Nasal Cannula Liberation: Who, When, and How?
High-flow nasal cannula (HFNC) is a first-line therapy for patients with acute respiratory failure. Despite increased HFNC utilization over recent years-accelerated in part by the COVID-19 pandemic-high-quality evidence to guide HFNC discontinuation is lacking. Decisions about when and how quickly to reduce flow rate, Fio2, or both simultaneously are frequently left to clinicians' discretion without clear guidance on an optimal approach. Failure to de-escalate HFNC support when clinically appropriate has many potential consequences, such as prolongation of ICU/hospital length of stay, increased health care costs, and reduced availability of limited hospital resources. With the goal of improving care efficiency and resource utilization among hospitalized patients with acute respiratory failure, we propose a standardized approach for HFNC discontinuation focused on "liberation" (similar to spontaneous breathing trials for patients undergoing mechanical ventilation), using a stepwise approach guided by physiology.
296. Shared Decision-Making in the ICU: Communicating With Patients Who Speak a Language of Lesser Diffusion.
Effective bidirectional communication is crucial during end-of-life decision-making, which requires clear understanding between clinicians and patients and their family members about treatment options, preferences, and goals of care. For those who have a non-English language preference or who have difficulty speaking, reading, writing, and understanding English, interpreters are essential. However, patients who speak rarer languages, known as languages of lesser diffusion (LLDs), such as Karen, spoken in Thailand and Myanmar, face unique challenges because of limited interpretation resources. In this work, we discuss the case of a Karen-speaking patient admitted to the ICU who lacked decision-making capacity, requiring the involvement of family members who also spoke Karen for a code status discussion. Despite efforts to find an interpreter, no Karen interpreter was available initially, complicating the communication and decision-making about changing the code status to do not resuscitate/do not intubate. A remote Karen interpreter was identified later, allowing for effective communication and clinician assurance that the family did understand the implications of their decision and had made it voluntarily. End-of-life decision-making is complex and challenging, requiring culturally sensitive communication. Patients who speak LLDs face unique difficulties in these discussions compared with those who speak more common languages because of the lack of interpretation resources. The purpose of this case report is to draw attention to these specific challenges and explore ethical concerns when engaging in decision-making conversations with patients and families who speak an LLD.
297. Physical Activity Measured by Hip-Anchored Accelerometry in Pediatric Pulmonary Hypertension: Association With Disease Severity and Estimation of Minimal Important Differences.
作者: Mark-Jan Ploegstra.;Rosaria J Ferreira.;Chantal Lokhorst.;Eva Gouwy.;Suzanne S J Schwartz.;Marlies G Haarman.;Matthieu Villeneuve.;Dimitri Stamatiadis.;Johannes M Douwes.;Rolf M F Berger.
来源: Chest. 2025年168卷1期200-222页
Pediatric pulmonary hypertension (PH) is a severe incurable disease with a poor prognosis. In pediatric PH, trial design is hampered by the absence of age-appropriate trial end points. This study evaluated physical activity (PA) measured by hip-anchored accelerometry as a potential trial end point in pediatric PH.
298. Modified Cuff Leak Test for Predicting the Risk of Reintubation in Patients With Invasive Mechanical Ventilation: A Multicenter, Single-Anonymized, Randomized Controlled Trial.
作者: Xiao Tang.;Yan-Mei Gu.;Yuan Shi.;Zhi-Ming Li.;Rui Cao.;Sheng-Gui Lu.;Yan-Bin Wu.;Yun-Feng Tao.;Zi-Yan Sun.;Yong-Jie Yin.;Cheng-Yi Liu.;Xiao-Bin Tang.;Gui-Fen Gan.;Xue-Jun Qin.;Dong Yin.;Hong-Bin Zhao.;Cheng-Ying Liu.;Lei Zhang.;Ping Fang.;Ling-Shuang Du.;Li Li.;Hai Tan.;Meng Li.;Ying-Ting Zuo.;Bing Sun.; .
来源: Chest. 2025年168卷1期119-130页
The cuff leak test (CLT) is an important tool to assess the risk of upper airway obstruction after extubation.
299. Trajectories of Interferon-Gamma Release Assay Results Over 2 Years in Independent Cohorts From China, South Africa, Tanzania, and the United States.
作者: Cheng Chen.;Hao Xue.;C Robert Horsburgh.;Maryam Amour.;Mark Hatherill.;Michele Tameris.;C Fordham von Reyn.;Christiaan Rees.;Ye Shen.;Helen McShane.;Alberto L García-Basteiro.;Donglin Liu.;Yijun Wang.;Ruvandhi R Nathavitharana.;Edward A Graviss.;Yan Shao.;Qiao Liu.;Wei Lu.;Limei Zhu.;Leonardo Martinez.
来源: Chest. 2025年168卷1期33-42页
There is an ongoing debate about whether clearance of Mycobacterium tuberculosis infection occurs and at what magnitude. Recent studies quantifying "uncertainty zones" of interferon-gamma release assays (IGRAs) provide a more stringent estimate of reversion.
300. Effect of Dupilumab on Health-Related Quality of Life and Respiratory Symptoms in Patients With COPD and Type 2 Inflammation: BOREAS and NOTUS.
作者: Surya P Bhatt.;Klaus F Rabe.;Nicola A Hanania.;Claus F Vogelmeier.;Mona Bafadhel.;Stephanie A Christenson.;Alberto Papi.;Dave Singh.;Elizabeth Laws.;Paula Dakin.;Jennifer Maloney.;Xin Lu.;Deborah Bauer.;Ashish Bansal.;Raolat M Abdulai.;Lacey B Robinson.
来源: Chest. 2025年168卷1期56-66页
Patient-reported outcomes should be considered alongside clinical assessments to guide therapy for COPD.
|